Previous Close | 28.51 |
Open | 28.59 |
Bid | 28.17 x 400 |
Ask | 28.20 x 400 |
Day's Range | 28.11 - 28.65 |
52 Week Range | 22.01 - 32.88 |
Volume | |
Avg. Volume | 1,914,179 |
Market Cap | 4.642B |
Beta (5Y Monthly) | 0.44 |
PE Ratio (TTM) | 12.36 |
EPS (TTM) | 2.28 |
Earnings Date | Jul 24, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 34.92 |
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alkermes' (ALKS) phase II Vibrance-2 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with narcolepsy type 2.
The trial will compare the safety and efficacy of ALKS 2680 with a placebo in adults with NT2.